Stabilitech appoints new commercial director
pharmafile | February 8, 2011 | Appointment | Manufacturing and Production | Donna Hackett, Stabilitch, appointment, manufacturing and production
Donna Hackett joins stabilisation company Stabilitch as commercial director.
She has 20 years pharma experience, most recently at pre-clinical, clinical and regulatory consultancy ProPharma Partners.
Prior to this she headed up the biopharmaceutical side of the commercialisation arm of University College London and before that was responsible for the commercialisation of BTG’s pharma portfolio.
Stabilitech chief executive Dr Barbara Domayne-Hayman said: “Over the past three years Stabilitech has developed and expanded its technology offering and we have generated great interest in our platform. Donna’s appointment will increase the company’s capabilities to commercialise its technology and maximise its value.”
Stabilitech’s research is focused on new technologies to stabilise vaccines, biopharmaceuticals and other biological products, removing the need for refrigeration.
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …






